News and Community

Aln-htt02, Alnylam Alny Stock, Alnylam Pharmaceuticals, Alnylam Rnai Roundtable, Brezosiran, Huntingtin, Huntingtin Lowering, Huntington's Disease, Huntington's Disease Clinical Trial, Huntington's Disease Treatment, Intrathecal Rnai Therapy, Mutant Huntingtin (mhtt), Phase 1b Clinical Trial Results, Rnai Therapeutics

October 23, 2026

Alnylam Reports Positive Phase 1b Brezosiran (ALN-HTT02) Data, Showing Deep and Durable Huntingtin Lowering in Huntington’s Disease

Disease, Eu Clinical Trial Authorization, Ferrer And Prilenia Therapeutics, Hd Research, Healthcare Technology, Huntington's Disease News, Huntington's Disease Treatment, Neurodegenerative Disease Research, Phase 3 Clinical Trial, Precise-hd Study, Pridopidine

October 22, 2026

Ferrer and Prilenia Receive EU Authorization to Launch Confirmatory PRECISE-HD Study of Pridopidine for Huntington’s Disease